New drug combo tested for Tough-to-Treat prostate cancer
NCT ID NCT05502315
Summary
This study is testing whether a combination of two drugs, cabozantinib and nivolumab, can help control advanced prostate cancer that has spread and no longer responds to standard hormone treatments. It will involve about 47 men who have already tried other therapies. The main goal is to see if the treatment can delay the cancer's growth for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California San Diego
RECRUITINGLa Jolla, California, 92093, United States
Contact Email: •••••@•••••
Contact
Contact
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Email: •••••@•••••
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact
Contact Email: •••••@•••••
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.